{
  "0": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes estrogen receptor antagonism in breast tissue, and provides additional correct and clinically relevant mechanistic detail without any inaccuracies or omissions."
  },
  "1": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately details the glucocorticoid receptor pathway, and provides relevant, correct additional explanation without any inaccuracies or omissions."
  },
  "2": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies TNF-α as the inhibited cytokine, provides accurate and clinically relevant reasoning, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "3": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the cellular target, thoroughly explains the mechanism of action, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "4": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies thioredoxin reductase as the enzyme inhibited by auranofin and provides a thorough, accurate explanation, but it omits specifying the mitochondrial isoform (thioredoxin reductase 2), which is a minor omission."
  },
  "5": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the GnRH receptor as the direct molecular target, accurately explains the mechanism of action, and provides clinically relevant details without any inaccuracies or omissions."
  },
  "6": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the molecular target, accurately describes its intracellular/nuclear location and mechanism, and all extra content is relevant and factually correct."
  },
  "7": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies VEGF as the key pathway, provides accurate context, and any additional details are factually correct and clinically relevant; there are no inaccuracies or omissions."
  },
  "8": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately describes the glucocorticoid receptor mechanism, and provides additional correct and clinically relevant details without any inaccuracies or omissions."
  },
  "9": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies IGF-1R as the direct molecular target, provides accurate and clinically relevant context about teprotumumab and its mechanism, and contains no inaccuracies or omissions."
  },
  "10": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the direct mediator, accurately describes the mechanism, and provides relevant, factually correct extra detail without any omissions or inaccuracies."
  },
  "11": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the molecular target (tRNA methyltransferase DNMT2/TRDMT1), the drug (azacitidine), and the mechanism (inhibition of cytosine-38 methylation in tRNA improves erythroid precursor function), fully covering all key clinical facts in the reference answer with accurate and relevant elaboration."
  },
  "12": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the specific molecular target, accurately describes its location, mechanism, and provides relevant additional details without any inaccuracies or omissions."
  },
  "13": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies TNF-α as the key molecular target, provides accurate and clinically relevant context about thalidomide, and contains no inaccuracies or omissions."
  },
  "14": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts, correctly identifies VEGF-A as the direct target, and provides accurate, relevant explanations without any errors or omissions."
  },
  "15": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the clinical scenario, explains the mechanism of action, distinguishes between possible agents, and precisely names the thrombopoietin receptor (MPL)–JAK2 kinase complex as the relevant molecular complex, covering all key facts in the reference answer with accurate and clinically relevant detail."
  },
  "16": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies VEGF-A as the key target, explains its central pathogenic role, references standard therapies, and appropriately contextualizes angiopoietin-2 as secondary; no omissions or inaccuracies."
  },
  "17": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CXCR4 as the receptor, thoroughly explains the pathophysiology, mechanism of action, and clinical benefit, and contains no inaccuracies or omissions compared to the reference."
  },
  "18": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the somatostatin receptor as the molecular target, whereas the reference specifies the interferon alpha receptor complex; this is a moderate factual error, though the rest of the content is relevant."
  },
  "19": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies transthyretin as the target, explains the mechanism of antisense oligonucleotide therapy, and clearly links TTR reduction to decreased amyloid deposition and clinical benefit, with no omissions or inaccuracies."
  },
  "20": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies 5-alpha reductase (specifically type II) as the target enzyme and provides relevant clinical context, but omits the full systematic enzyme name (\"3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 2\") given in the reference."
  },
  "21": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical scenario, mechanism of action, and the main drug class, but incorrectly names SSTR2 instead of SSTR5 as the primary molecular target, missing the key fact required by the reference answer."
  },
  "22": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies PDE4 as the relevant molecular target, whereas the reference specifies cGMP-specific 3',5'-cyclic phosphodiesterase; this is a moderate factual error, though the rest of the explanation is detailed and relevant."
  },
  "23": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies thymidylate synthase as the directly inhibited enzyme, explains the mechanism, and provides relevant, accurate extra detail without any errors or omissions."
  },
  "24": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the vitamin D receptor (VDR), explains its nuclear transcription factor role, and details its mechanism and clinical relevance, fully matching the reference answer with no omissions or inaccuracies."
  },
  "25": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies cyclooxygenase (COX) as the molecular target, missing the key fact that the question describes an NSAID acting via inhibition of cGMP-specific phosphodiesterase (e.g., indomethacin), not COX; while the explanation is otherwise relevant, this is a moderate factual error."
  },
  "26": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the AT1 receptor, covers all key clinical facts from the reference, and provides accurate, relevant explanations without any errors or omissions."
  },
  "27": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies ornithine decarboxylase as the inhibited enzyme and provides a thorough, accurate, and clinically relevant explanation without any errors or omissions."
  },
  "28": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the clinical context and discusses relevant epigenetic targets, including HDAC, DNMT, and LSD1/KDM1A, but ultimately selects LSD1/KDM1A as the primary target, which is not the reference answer (histone deacetylase); this constitutes a moderate factual error."
  },
  "29": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the interferon-α/β receptor (IFNAR1/IFNAR2 heterodimer) as the primary mediator, matching the reference answer, and provides accurate, clinically relevant explanation with no omissions or inaccuracies."
  },
  "30": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the interferon alpha (type I interferon) receptor complex as the direct target, accurately explains the JAK-STAT mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "31": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies IL-6 as the target, thoroughly explains its pathogenic role in MCD, and clearly describes how IL-6 inhibition alleviates all key clinical features; all content is accurate, relevant, and free of omissions or errors."
  },
  "32": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies thymidylate synthase as the directly inhibited enzyme, explains the drug mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "33": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "34": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the growth hormone receptor as the target, explains the mechanism of action of pegvisomant, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "35": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies nintedanib and its inhibition of PDGFR, but fails to mention VEGFR as the specific receptor in the reference answer, thus missing a key fact; otherwise, the explanation is accurate and relevant."
  },
  "36": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies dihydrofolate reductase as the primary molecular target, explains methotrexate’s mechanism, and provides clinically relevant, accurate elaboration without any omissions or inaccuracies."
  },
  "37": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the Vitamin D Receptor (VDR) as the principal mediator, accurately describes the activation pathway, mechanism of action, and relevant gene transcription effects, with no inaccuracies or omissions."
  },
  "38": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the intracellular receptor, thoroughly explains the mechanism, and provides relevant clinical context without any inaccuracies or omissions."
  },
  "39": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor and provides accurate, clinically relevant mechanistic details without any errors or omissions."
  },
  "40": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies somatostatin receptor subtype 2 (SSTR2) as the primary molecular target, provides accurate and clinically relevant additional details, and contains no inaccuracies or omissions."
  },
  "41": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies DNA methyltransferase as the inhibited enzyme and provides relevant clinical context, but it omits the specific isoform (tRNA (Cytosine(38)-C(5))-Methyltransferase) named in the reference, which is a key detail."
  },
  "42": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the direct molecular target as the interleukin-6 receptor (IL-6R), which encompasses the soluble IL-6 receptor subunit alpha, and provides accurate, relevant clinical context; however, it does not explicitly specify the \"soluble\" or \"alpha subunit\" aspect, representing a minor omission."
  },
  "43": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the spike (S) protein as the target and accurately explains its role in viral entry and antibody neutralization, with all content factually correct and clinically relevant."
  },
  "44": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies C5 as the inhibited component, accurately explains its role in MAC formation, and provides relevant examples without any errors or omissions."
  },
  "45": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies DNA methyltransferase as the directly inhibited enzyme, explains the drug mechanism, and provides relevant clinical context without inaccuracies or omissions."
  },
  "46": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the vitamin D receptor (VDR) as the molecular target and provides a detailed, accurate, and clinically relevant explanation without any inaccuracies or omissions."
  },
  "47": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CXCR4 as the molecular target, thoroughly explains its role in leukocyte retention, relates it to WHIM syndrome, and provides accurate, relevant extra details without any inaccuracies or omissions."
  },
  "48": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies thymidylate synthase as the directly inhibited enzyme, provides accurate and clinically relevant context about actinic keratoses and 5-FU, and contains no inaccuracies or omissions."
  },
  "49": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HIF-2α as the direct target, explains the VHL disease mechanism, and clearly links HIF-2α inhibition to the pathophysiology; all key facts are covered with relevant, accurate detail and no errors."
  },
  "50": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies microtubules as the primary structure targeted, explains the mechanism (binding tubulin, inhibiting polymerization), and relates it to the clinical context; all key facts are covered with no inaccuracies or omissions."
  },
  "51": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies thalidomide, its indication, and its mechanism (inhibition of TNF via mRNA degradation), with all additional content accurate and clinically relevant."
  },
  "52": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the specific enzyme, provides its full name, and accurately explains the mechanism and clinical relevance without any inaccuracies or omissions."
  },
  "53": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the IL-12/IL-23 receptor complex instead of the interferon alpha receptor complex, which is the key fact. While it correctly describes JAK-STAT signaling and immune modulation, this moderate factual error significantly impacts the clinical accuracy."
  },
  "54": {
    "score": 5.0,
    "explanation": "5: Fully correct—covers all key facts from the reference answer, accurately identifies the glucocorticoid receptor as the molecular target, and provides relevant, factually correct, and clinically pertinent additional explanation without any errors or omissions."
  },
  "55": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CD20 as the target, provides accurate and clinically relevant explanation, and includes all key facts from the reference answer with no inaccuracies or omissions."
  },
  "56": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies \"viral DNA polymerase\" as the primary target, matches all key clinical facts, and provides accurate, relevant additional explanation without any errors or omissions."
  },
  "57": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies RANKL as the direct molecular target, explains the mechanism, and provides relevant, accurate additional detail without any inaccuracies or omissions."
  },
  "58": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies complement C5 as the direct molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "59": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the direct molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "60": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as the molecular target, explains its intracellular location and mechanism, and provides relevant clinical context; all content is accurate and clinically relevant with no omissions."
  },
  "61": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the histamine H2 receptor as the molecular target, provides accurate and clinically relevant explanation, and includes a correct summary table without any inaccuracies or omissions."
  },
  "62": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX), specifies COX-2 as the primary target in inflammation, and explains the mechanism, but does not explicitly use the full name \"Prostaglandin G/H Synthase 2 (COX-2)\" as in the reference; this is a minor wording inaccuracy."
  },
  "63": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies CSF1R as the receptor, provides accurate and clinically relevant explanation, includes all key facts from the reference, and adds correct, relevant details about nintedanib and its targets without any inaccuracies or omissions."
  },
  "64": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains the mechanism, and provides only relevant, accurate, and clinically appropriate information with no omissions or errors."
  },
  "65": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the principal target, covers all key clinical facts from the reference, and provides accurate, relevant explanations without any errors or omissions."
  },
  "66": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies CD20 as the target and provides a clinically relevant, accurate explanation with no errors or omissions."
  },
  "67": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough explanation and correctly identifies mifepristone and its receptor targets, but it incorrectly states that the glucocorticoid receptor is the primary molecular target for hyperglycemia control, whereas the reference specifies the progesterone receptor; thus, a moderate factual error is present."
  },
  "68": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies TNF-α as the primary target, whereas the question specifically describes a drug with anti-angiogenic effects via inhibition of a signaling protein involved in new blood vessel formation—characteristics of VEGF-A, not TNF-α. While TNF-α is relevant in inflammatory disease, this is a moderate factual error regarding the drug’s mechanism."
  },
  "69": {
    "score": 5.0,
    "explanation": "5: All key facts are present, including the correct enzyme name and its role; additional explanation is accurate and clinically relevant."
  },
  "70": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies thyroid peroxidase as the target enzyme, explains its role in iodination and coupling, and provides relevant clinical context without inaccuracies or omissions."
  },
  "71": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the glucocorticoid receptor as primary, explains the mechanism, and relates it to MS relapse management; no inaccuracies or omissions."
  },
  "72": {
    "score": 2.0,
    "explanation": "2: The model answer identifies COX-2 as the primary target, which is a moderate factual error since the reference specifies COX-1; it also provides relevant context but misses the key fact required."
  },
  "73": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies IL-1β as the targeted cytokine and thoroughly explains the molecular mechanism, pathophysiology, and rationale for therapy, with all content factually accurate and clinically relevant."
  },
  "74": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the vasopressin V2 receptor as the molecular target, provides accurate and clinically relevant explanation, and contains no inaccuracies or omissions."
  },
  "75": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies the drug and its signaling pathway, and provides a detailed, accurate description of downstream signaling (ISGF3 complex), but omits the reference answer’s key fact: the essential mediator is the interferon alpha receptor complex, not ISGF3. This is a moderate omission, as the question specifically asks for the molecular complex mediating the drug’s effect."
  },
  "76": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the vitamin D receptor (VDR) as the direct molecular target, thoroughly explains the mechanism, and provides only relevant, accurate, and clinically pertinent details without any omissions or inaccuracies."
  },
  "77": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target and provides a clear, accurate, and clinically relevant explanation without any omissions or inaccuracies."
  },
  "78": {
    "score": 5.0,
    "explanation": "5: All key clinical facts are covered, including the correct identification of the molecular target (bacterial RNA polymerase), its role in transcription, and the mechanism of fidaxomicin; extra details are accurate and clinically relevant."
  },
  "79": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies C5 as the target, explains the mechanism, and links it to symptom relief in PNH without any errors or omissions."
  },
  "80": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the thrombopoietin receptor (c-MPL) as the target, provides the drug name, and offers accurate, clinically relevant explanation without any errors or omissions."
  },
  "81": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the estrogen receptor as the molecular target, explains the rationale, and provides relevant, accurate extra detail without any errors or omissions."
  },
  "82": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the progesterone receptor as the specific molecular target, provides accurate and clinically relevant explanation, and contains no errors or omissions."
  },
  "83": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies α4β7 integrin as the molecular target and provides a clinically relevant, accurate explanation without any omissions or inaccuracies."
  },
  "84": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the relevant intracellular receptor, provides accurate and clinically relevant details about budesonide, its mechanism, and its use in Crohn’s disease, with no inaccuracies or omissions."
  },
  "85": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the molecular target, thoroughly explains the clinical context and mechanism, and contains no inaccuracies or omissions."
  },
  "86": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor as the primary target, provides accurate and clinically relevant explanation, and includes only factually correct, relevant extra details without any omissions or inaccuracies."
  },
  "87": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies VEGF as the most direct molecular target, provides accurate context about thalidomide’s mechanisms, and includes only relevant, factually correct information without omissions or inaccuracies."
  },
  "88": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies SSTR2 as the primary molecular target, provides accurate and clinically relevant context, and contains no inaccuracies or omissions compared to the reference answer."
  },
  "89": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, correctly identifies the estrogen receptor as the target, and provides accurate, relevant clinical context and mechanistic explanation without any inaccuracies or omissions."
  },
  "90": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies tryptophan hydroxylase as the inhibited enzyme and provides accurate, relevant explanation, but omits the specific isoform \"tryptophan 5-hydroxylase 1\" named in the reference, which is a minor omission."
  },
  "91": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed rationale and discusses relevant amino acids (glycine and taurine) involved in bile acid conjugation, but it does not identify asparagine, the correct answer, and instead incorrectly concludes taurine. This represents a moderate factual error and covers less than 70% of the key facts."
  },
  "92": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the molecular target as Interleukin-1 receptor type I (IL-1R1), provides accurate and relevant clinical context, and contains no inaccuracies or omissions."
  },
  "93": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical facts from the reference, accurately identifies the histamine H2 receptor as the target, explains the mechanism in detail, and provides clinically relevant, correct additional information without any inaccuracies or omissions."
  },
  "94": {
    "score": 5.0,
    "explanation": "5: Fully correct—identifies the histamine H2 receptor as the direct target, accurately explains the mechanism, and provides relevant clinical context with no errors or omissions."
  },
  "95": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies the glucocorticoid receptor, explains the clinical context, mechanism of action, and relevance, with no omissions or inaccuracies."
  },
  "96": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies cyclooxygenase (COX), including both COX-1 and COX-2, and explains the mechanism, but does not specify COX-2 as the primary therapeutic target in inflammation as in the reference answer; this is a minor omission."
  },
  "97": {
    "score": 5.0,
    "explanation": "5: Fully identifies the progesterone receptor as the specific molecular target, provides correct and relevant mechanism, and contains no inaccuracies or omissions."
  },
  "98": {
    "score": 4.0,
    "explanation": "4: The model answer correctly identifies the VEGF pathway as the target and explains the mechanism, but does not specify \"VEGF-A\" as in the reference answer; this is a minor omission since VEGF-A is the key isoform involved."
  },
  "99": {
    "score": 5.0,
    "explanation": "5: The model answer correctly identifies HMG-CoA reductase as the inhibited enzyme and provides a clear, clinically relevant explanation matching all key facts in the reference answer with no inaccuracies or omissions."
  }
}